Published in Tuberculosis Week, June 29th, 2009
The two organizations will share their expertise and resources in the development of TMC207, which could become the first TB drug with a new mechanism of action in 40 years. The interim data from an ongoing Phase II study of TMC207 were recently published in the New England Journal of Medicine. In the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Tuberculosis Week